Ruling may broaden Ottawa’s reach over patents

Seven pharmaceutical companies, along with a string of intellectual property organizations and patients’ groups acting as interveners, that challenged the constitutionality of new regulations intended to lower patented drug prices were rebuffed after Quebec Superior Court found that the price control of patented drugs falls within the scope of the federal government’s powers over patents.

The long-awaited decision will likely have a substantial impact on the pharmaceutical industry in Canada, will compel Ottawa to overhaul its regulatory approach and guidelines over patented drug pricing, and may even broaden the federal government’s reach to regulate other intellectual property, according to legal experts.

Read More

This story was originally published in The Lawyer’s Daily.

2 thoughts on “Ruling may broaden Ottawa’s reach over patents

Leave a Reply

Your email address will not be published. Required fields are marked *